Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition for treating diabetes and application of medicament composition

A composition and diabetes technology, applied in the field of medicine, can solve the problems of subcutaneous hemorrhage, aggravated ischemia, repeated injections, etc., and achieve the effect of improving blood lipid level, good therapeutic effect, and improving blood sugar

Active Publication Date: 2012-07-04
LUNAN PHARMA GROUP CORPORATION
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(2) On the basis of diabetic microangiopathy, atherosclerosis of large and medium arteries is combined, which aggravates the ischemia of related organs, thus accelerating organ dysfunction and failure
However, in this treatment plan, low molecular weight heparin is used for injection administration. The biggest disadvantage of low molecular weight heparin injection preparations in clinical application is repeated injections. Subcutaneous injections often cause subcutaneous bleeding, which is difficult for patients who need long-term medication.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition for treating diabetes and application of medicament composition
  • Medicament composition for treating diabetes and application of medicament composition
  • Medicament composition for treating diabetes and application of medicament composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 tablet

[0034] Prescription rosuvastatin calcium 1g (calculated as rosuvastatin, the same below)

[0035] Low-molecular-weight heparin sodium 5g (calculated as low-molecular-weight heparin, the same below)

[0036] Pioglitazone hydrochloride 120g (calculated as pioglitazone, the same below)

[0037] Microcrystalline Cellulose 1000g

[0038] 2% hydroxypropyl methylcellulose solution appropriate amount

[0039] Low-substituted hydroxypropyl cellulose 80g

[0040] Magnesium Stearate 50g

[0041] Preparation process: Rosuvastatin calcium, low-molecular-weight heparin sodium and pioglitazone hydrochloride passed through a 100-mesh sieve, microcrystalline cellulose and low-substituted hydroxypropyl cellulose passed through a 80-mesh sieve, and the prescribed amount of rosuvastatin calcium, low-molecular-weight hydroxypropyl cellulose was weighed. Molecular heparin sodium and pioglitazone hydrochloride are mixed evenly with low-substituted hyd...

Embodiment 2

[0042] Example 2 tablet

[0043] Prescription Rosuvastatin Calcium 1g

[0044] Low molecular weight heparin sodium 1000g

[0045] Pioglitazone Hydrochloride 3g

[0046] Microcrystalline Cellulose 2000g

[0047] 2% hydroxypropyl methylcellulose solution appropriate amount

[0048] Low-substituted hydroxypropyl cellulose 700g

[0049] Magnesium Stearate 60g

[0050] The preparation process is the same as in Example 1.

Embodiment 3

[0051] Example 3 tablet

[0052] Prescription Rosuvastatin Calcium 1g

[0053] Low molecular weight heparin sodium 1000g

[0054] Pioglitazone Hydrochloride 120g

[0055] Microcrystalline Cellulose 2000g

[0056] 2% hydroxypropyl methylcellulose solution appropriate amount

[0057] Low-substituted hydroxypropyl cellulose 900g

[0058] Magnesium Stearate 80g

[0059] The preparation process is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine, and relates to a medicament composition for treating diabetes and application of the medicament composition, in particular to application of the medicament composition in treatment of diabetic nephropathy and diabetic merged hyperlipidemia. For better treating the diabetes and complications thereof, the invention provides the medicament composition. The medicament composition contains hydroxymethyl glutaryl coenzyme A reductase inhibitor, glycosaminoglycan and insulin sensitizer serving as active ingredients, and particularly contains low molecular weight heparin, pioglitazone and rosuvastatin.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for treating diabetes and its new application, in particular to the application of the pharmaceutical composition for treating diabetic nephropathy and diabetes complicated with hyperlipidemia. Background technique [0002] Diabetes mellitus (DM) is a group of syndromes caused by environmental and genetic factors. Its basic pathological features are absolute or relative insufficiency of insulin secretion, or peripheral tissue insensitivity to insulin, mainly causing glucose metabolism disorders. A systemic disease involving disorders of fat and protein metabolism. Many studies have confirmed that obese patients have lipid metabolism disorders long before abnormal glucose metabolism, often accompanied by varying degrees of hyperlipidemia. The main abnormalities of lipid metabolism are elevated blood triglyceride (TG), decreased high-density lipopro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/726A61K31/727A61P3/10A61K31/4439A61K31/505
Inventor 赵志全姚景春
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com